Trial Profile
A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs ONL 1204 (Primary)
- Indications Retinal detachment
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors ONL Therapeutics
- 11 Apr 2023 According to an ONL Therapeutics media release, the company will deliver a podium presentation reviewing the results from this study at the upcoming annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
- 07 Oct 2022 Status changed from active, no longer recruiting to completed.
- 12 Jul 2022 According to an AmbioPharm media release, enrollment has been completed in this study.